40 research outputs found
Hepatitis A vaccine in pediatric patients affected by metabolic liver diseases
No full textTwenty children with a variety of metabolic liver diseases were given two doses of hepatitis A vaccine. Adverse reactions were mild. All subjects responded to vaccine with seroconversion to hepatitis A virus antibodies after the first dose, regardless of transaminase values, and had a booster effect from the second doses
Hepatitis A vaccination in chronic carriers of hepatitis B virus
No full textBecause hepatitis A infection may be more severe in patients with chronic liver disease, we vaccinated 33 children who were chronic HBsAg carriers against hepatitis A virus. Anti-hepatitis A virus seroconversion rates after the first, second, and third doses were 90.9%, 96.9%, and 100%, respectively
HBV-DNA INTEGRATION AND HEPATOCELLULAR CARCINOMA IN THREE CHILDREN WITH HBV-PERINATAL INFECTION
No full textHBV-PERINATAL INFECTION, HBV-DNA INTEGRATION AND HEPATOCELLULAR CARCINOMA (HCC) IN THREE CHILDREN
No full textLe urgenze ematologiche
No full textIntroduzione
M. Scudeletti
La trombocitopenia immune
M. Cavalleri, P. Pitto, S. Timitilli, M. Scudeletti
Approccio dell’internista alla leucemia acuta
G.L. Michelis
Sindrome emolitico-uremica atipica e porpora trombotica trombocitopenica
M. Brignone
I linfomi aggressivi a rapida crescita
M. Cavaliere
L’emofilia A acquisita
G.A. Berisso
La gestione delle complicanze acute del paziente con mieloma multiplo
R. Goretti
Le complicanze trombo-emboliche nel paziente ematologico
S. Panarello, C. Fioravanti, F. Raggi, G. Antonucci
Come affrontare il paziente con leucocitosi e linfocitosi
C. Venturino, R. Tassara
Come affrontare il paziente con adenomegalia
P. Gnerre, N. Artom, E. Schiavetta, L. Parodi
Come affrontare il paziente con splenomegalia
P. Gnerre, N. Artom, E. Schiavetta, L. Parodi
Come affrontare il paziente con leucopenia
G. Pastori, R. Tassara
Come affrontare il paziente con trombocitosi
L. Rebella, R. Tassara
Policitemia vera o morbo di Vaquez
E. Arboscello
Approccio all’adulto con piastrinopenia
R. Tassara, L. Paris
La gestione delle infezioni nel paziente oncoematologico
A.L. Garlaschelli, F. Artom
La gammopatia di origine indeterminata
S. Timitilli, M. Cavalleri, M. Scudeletti
La malattia di Gaucher
M. Cavaliere
Come affrontare i pazienti con..
Immunogenicity of heptavalent pneumococcal vaccine and hexavalent vaccine, co-administered to italian infants at 3, 5 and 11-12 months of age
No full textUniversal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria, Italy
No full textLiguria was the first Italian Administrative Region, since 2003, to actively recommend free-of-charge immunisation, of all infants, with heptavalent Pneumococcal Conjugate Vaccine (PCV-7), within a research pilot-project. Vaccination coverage among infants rapidly increased from 42.8% in 2003 to 83.3% in 2004, progressively reaching levels of 93.4% in 2007. Two scientific projects have been carried out, aimed: (i) to assess the immunogenicity of PCV-7 and of a hexavalent vaccine Diphtheria-Tetanus-Trivalent Acellular Pertussis-Hepatitis B-Inactivated Polio Virus-Haemophilus influenzae type B (DTaP-HBV-IPV-Hib) when co-administered to healthy infants at 3, 5 and 11-12 months of age (routine schedule), and (ii) to evaluate the effect of the immunisation campaign in preventing pneumococcal-associated hospitalisations. Results in 151 infants showed the high immunogenicity of the vaccines, seroprotection rates, measured 1 month after the third dose, ranging between 97.3% (serotype 6 B) and 100% (serotypes 4 and 9 V) for PCV-7 and between 99.3% and 100% against common antigens of hexavalent vaccine. Monitoring nearly 70,000 children, aged 0-24 months, during the period 2000-2007, and comparing hospitalisation rates occurred in subjects belonging to birth cohorts before and after the introduction of widespread immunisation, a significant decline for all-cause and pneumococcal pneumonia and for acute otitis media was observed, with preventive fractions of 15.2%, 70.5% and 36.4%, respectively
Chronic hepatitis C in children: The pathological and clinical spectrum
No full textBACKGROUND & AIMS:
Apart from the high-risk groups, the pathology of chronic hepatitis C in children is not well known. The aim of this study was to investigate the morphology of chronic hepatitis C in children without any underlying systemic disease and to evaluate its relationship to clinicovirological factors.
METHODS:
Liver biopsy specimens from 80 children positive for antibody to hepatitis C virus were evaluated using a semiquantitative scoring system.
RESULTS:
Chronic hepatitis was mild in most cases but had high-grade activity in 17 children (21.2%). A significant association was found between the grade of focal necrosis and alanine transaminase levels (P < 0.003). Fibrosis was absent in 22 cases (27.5%), mild in 44 (55%), and moderate in 13 (16.2%). Only 1 patient had cirrhosis. A significant relationship was detected between fibrosis scores and (1) duration of disease (P < 0.03); (2) portal inflammation (P < 0. 002); and (3) interface hepatitis (P < 0.003).
CONCLUSIONS:
In otherwise healthy children, chronic hepatitis C is a morphologically mild disease in most cases. Fibrosis increases with the duration of disease, suggesting that end-stage disease may develop in young adulthood. Alanine transaminase levels correlate with intralobular focal necrosis but not with other lesions. In this respect, liver biopsy retains its importance in the management of chronic hepatitis C in children.
I.F. = 12.455
Long-term interferon-alpha treatment of childrenwith chronic hepatitis delta: a multicentre study.
No full textWe assessed the efficacy of prolonged interferon-alpha (IFN) therapy in children with chronic hepatitis caused by hepatitis delta virus (HDV) by treating 26 paediatric cases with IFN-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 (medium-term group MTG) or 24 months (long-term group, LTG). Compliance and tolerability were acceptable. At the end of therapy a complete biochemical response [normalization of alanine aminotransferase (ALT)] occurred in 12 children (5/13 in MTG and 7/13 in LTG). A relapse occurred after stopping IFN in 10 cases (five in MTG and five in LTG). Two patients from the LTG had normal liver function tests during 12 months of follow-up. Six of the eight hepatitis B e antigen (HBeAg) positive children lost HBeAg, while all six hepatitis B virus (HBV) DNA positive patients lost HBV DNA during treatment. HBeAg reappeared later in two children. HDV RNA, present in 10/10 cases of MTG before treatment, persisted after 12 months IFN therapy in 3/10. One year after stopping therapy, 8/10 patients were again HDV RNA positive. Two children cleared hepatitis delta antigen (HDVAg) from the liver. No significant improvements in liver histology were seen in both groups. Our experience suggests that IFN-alpha treatment in children with chronic type D hepatitis has a transient effect, and long-term treatment does not appear to induce a greater therapeutic benefit in terms of biochemical and virological respons
